VANCOUVER, BC – TheNewswire – April 18, 2022 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE:IZO) (CNSX:IZO.CN) (OTC:IZOZF) (FSE:1R3), an IzoView company , the dedicated breast CT (computed tomography) imaging platform for the more accurate detection and diagnosis of breast cancer, announces it has partnered with new investor awareness consultants and investor relations services. In an effort to educate new audiences and demographics about the company’s value proposition and emerging catalysts regarding potential investments, the company has engaged Blaze Capital and Westmount Capital.
Blaze Capital, founded by stockbroker Mr. Justin Caron, has amassed over 40,000 subscribers on YouTube, with over 4 million video views and over 100 million minutes of watch time. In addition to video content in the stock market, Blaze Capital provides investors with a place within a stock market community where they can join the thousands of users active on their investment portal, participate in paid stock-focused chat rooms, and subscribe to their paid newsletter for market insights and access to Mr. Caron’s equity portfolio positions. With a reputable audience that continues to grow, Blaze Capital recently began offering investor awareness services by partnering with select small-cap Canadian securities firms. Blaze Capital will showcase Izotropic across all its platforms by showcasing the company’s upcoming development progress and news flow through a series of 30 YouTube videos and ongoing coverage of its investor database through its paid newsletter.
“If we look at the demographics of Blaze Capital’s audience, nearly 90% are under the age of 44 and more than 30% of their total audience is female,” said Dr. John McGraw, CEO of Izotropic. “While patients in this age range may not be regularly imaged for breast cancer, we know that the younger a patient is at breast cancer onset, the more aggressive the cancer tends to be, and unfortunately harder to see on imaging due to higher breast densities associated with breast cancer. We also know that investors in this age group value socially responsible investing and invest earlier and more than previous generations 1. Our partnership with Blaze Capital is one of many planned initiatives to get our message across to this powerful younger group potential investors.”
The terms of the agreement are for USD 50k with coverage commencing April 19, 2022, and have no definite end date; instead, the length of the agreement will be dictated by Izotropic’s news flow over time to generate the specified number of videos showcasing the company’s progress.
To further diversify Izotropic’s investor base and reach, the company has engaged Swiss-based Westmount Capital to provide European investor relations services in Europe’s leading financial capitals. Westmount Capital will provide Izotropic exposure and introductions to its network of high net worth investors, family offices, institutional brokers, analysts and institutional fund managers, and companies and entrepreneurs participating in the MedTech sector across Europe, to which Izotropic will give individual presentations. † They will assist in the translation of corporate material and the planning and preparation of possible European investment conferences. The terms of the agreement are CHF 8,000 (eight thousand Swiss francs) per month for an initial term of three months with an option to continue monthly and for 200,000 stock options granted to the Westmount team at an exercise price of $0.65 . The stock options are effective for a term of one (1) year, with a vesting schedule of 50% after 30 calendar days and 50% after 90 calendar days.
ON BEHALF OF THE BOARD OF DIRECTORS
dr. John McGraw, CEO
Contact person for investor relations:
Free: 1-833-IZOCORP ext.1
Contact person for media inquiries:
Free: 1-833-IZOCORP ext.3
About Izotropic Corporation:
Izotropic Corporation is the only publicly traded company to commercialize a dedicated breast CT imaging platform, IzoView, for more accurate breast cancer detection and diagnosis. To accelerate patient and healthcare provider access to IzoView, Izotropic’s first clinical trial aims to demonstrate superior performance of diagnostic breast CT imaging over diagnostic mammography procedures. screening in radiology, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can be found on its website at izocorp.com and by viewing its profile on SEDAR at sedar.com.
This document may contain statements that are “forward-looking statements”, which are based on management’s current estimates, assumptions, projections and expectations of management, the company’s business and its knowledge of the relevant market and economic environment in which it operates. The Company has attempted, wherever possible, to identify such information and statements by using words such as “anticipate,” “believe,” “propose,” “estimate,” “expect,” “intend,” “may,” “plan,” “forecast,” “project,” “target,” “potential,” “will,” “should,” “could,” “should,” “continue,” “consider,” and other similar expressions and derivations thereof in connection with any discussion of future events, trends or prospects or future operating or financial performance, although not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict, and as such could cause future results of the company’s operations to differ materially from the content and implications of such statements . Forward-looking statements are only relevant as of the date they are made, and the company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of future events or conditions, unless otherwise required to do so according to the law. Neither the Company nor its shareholders, officers and advisers shall be liable for any action and the results of any action taken by any person based on the information contained herein, including but not limited to the purchase or sale of securities from the company. Nothing in this document should be construed as medical or other advice of any kind. All images are for illustrative purposes only. IzoView is not yet approved for sale.
Copyright (c) 2022 TheNewswire – All rights reserved.
The preceding article is from one of our external contributors. It does not represent Benzinga’s opinion and has not been edited.
This post Izotropic Moves to Teach New Breast CT Demographics, Hires New Consultants for Investor Relations and Awareness
was original published at “https://www.benzinga.com/22/04/26774931/izotropic-moves-to-educate-new-demographics-on-breast-ct-engages-new-consultants-for-investor-relati”